Vir Biotechnology expands board to eight, appoints Timothy Coughlin as Audit Chair

Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

• medium

  Board expanded from seven to eight directors with appointment of Timothy Coughlin, CPA, as Class III director serving through 2028 annual meeting. This is a net addition rather than replacement of departing member.

  Item 5.02 verify on EDGAR →
• medium

  Coughlin immediately appointed Chair of Audit Committee, bringing CPA credentials to key financial oversight role. Audit Committee oversees financial reporting, internal controls, and external auditor relationships.

  Item 5.02 verify on EDGAR →
• low

  New director receives standard non-employee compensation including automatic stock option and RSU grants under 2019 Equity Incentive Plan, consistent with existing director pay framework disclosed in 2026 proxy.

  Item 5.02 verify on EDGAR →